Caitong International Asset Management’s Caribou Biosciences CRBU Stock Holding History

Caitong International Asset Management’s Portfolio CRBU Stock Details CRBU Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$6	Buy	+3	New	+$5	﹤0.01%	2227

Other funds holding CRBU

Pfizer New York $239M AUM 232.47% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Caitong International Asset Management's CRBU Position: Q1 2026 in Review

Caitong International Asset Management opened a new position in Caribou Biosciences (CRBU) in Q1 2026: 3 shares worth $6. The stake represents ﹤0.01% of the portfolio and ranks #2227 among its holdings.

137 funds tracked by Wall St. Rank hold CRBU as of Q1 2026.

Caitong International Asset Management held 3 shares of Caribou Biosciences worth $6 as of Q1 2026.
Caribou Biosciences was a new Caitong International Asset Management position in Q1 2026.
Caribou Biosciences made up ﹤0.01% of Caitong International Asset Management's portfolio in Q1 2026, its #2227 holding.
137 funds tracked by Wall St. Rank held Caribou Biosciences as of Q1 2026.

Based on Caitong International Asset Management's 13F filing for Q1 2026, filed 11 May 2026.